Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy by Foo, J. et al.
OR I G I N A L R E S E A R C H
Cost-consequence analysis for human
recombinant growth hormone (r-hGH) treatment
administered via different devices in children with
growth hormone deficiency in Italy
This article was published in the following Dove Press journal:






1Global Health Economics, Mapi Group
(An ICON plc Company), Houten, The
Netherlands; 2Department of Pediatrics,
IRCCS Istituto Giannina Gaslini Institute,
University of Genova, Genova, Italy;
3Department of Clinical Medicine and
Surgery, University Federico II of Naples,
80131 Napoli, Italy; 4Global Health
Economics, ICON plc, London, UK;
5Department of Drug Science, Pavia
University, Pavia, Italy; 6SAVE Studi –
Health Economics & Outcomes
Research, Milan, Italy
Background: The objective of this analysis was to evaluate the cost-consequence of
recombinant human growth hormone (r-hGH) administered via the easypod auto-injector
(Merck, Darmstadt, Germany) versus conventional devices in children with growth hormone
deficiency in Italy.
Methods: A patient-level simulation, decision-analytical model was developed to estimate
the average height gains and growth hormone treatment costs for a cohort of boys and girls
until their bone maturation age. The calculations were performed using listed growth
hormone drug prices (base case) and a scenario analysis was also conducted using published
tender prices. Costs were discounted at 3%.
Results: Due to improved adherence and earlier identification of poor responders, patients
receiving somatropin with easypod gained, on average, 3.2 cm more than patients receiving
other r-hGH treatments. Somatropin with easypod had the second highest total cost including
wastage (€96,710), but had the second lowest cost per cm gained (€7699/cm). In the scenario
analysis, somatropin with easypod had the lowest cost per cm gained (€4708/cm) amongst all
of the compared treatments.
Conclusion: Somatropin with easypod can be cost-saving versus all other r-hGH treatments
except Omnitrope when listed drug prices are considered and can be cost-saving versus all
other r-hGH treatments when tender drug prices are considered. The easypod device also
facilitates cost savings in terms of reduced wastage.
Keywords: easypod, growth hormone treatment, growth hormone deficiency, cost-
consequence analysis
Introduction
Recombinant human growth hormone (r-hGH) is used to treat growth hormone
deficiency (GHD) in children and adults.1 Early intervention with long-term
r-hGH treatment improves adult stature, with some patients reaching target final
height.
However, there are a number of issues related to r-hGH treatment. Firstly, lack
of adherence hampers growth potential: poor (or non-) adherence is associated with
both individual and social treatment failures, such as less favorable clinical out-
comes, lower quality of life and higher health care costs.2 Secondly, an equally
important issue is poor response to r-hGH therapy (ie, not leading to significant
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catch-up growth). This can be measured in terms of
change in height standard deviation score (HtSDS). Poor
response can be prevented or corrected by adapting the
treatment following the relevant guidelines. Thirdly, there
is evidence that actual r-hGH consumption is much higher
than anticipated, suggesting substantial wastage.3
Several devices for r-hGH administration have been
developed that can be grouped into five broad categories
including syringes with needle, injection pens, self-injec-
tion pens, needle-free devices and electronic devices.
Easypod®, the electronic auto-injector device, is the
only device that allows for adherence monitoring. It has
a number of features, including pre-set dosing, adjustable
injection settings and accurate monitoring of treatment
adherence by an injection log that records injection his-
tory which can be accessed by patients or downloaded at
their clinic to show which injections, if any, have been
missed.4
Early identification of adherence levels to r-hGH ther-
apy may improve the cost-effectiveness of the treatment5,6
through optimization of patients’ management and cost
savings. Via easypod, the clinician has the necessary infor-
mation to correctly identify patients with high adherence
and poor response due to decreased sensitivity to growth
hormone (GH) (GH “resistant”), and subsequently
increase the GH dose in line with the approved dose
range for GHD patients.
Furthermore, the use of the easypod device, through
its unique capacity for automatic dose adjustment and
dosage optimization across cartridges, minimizes product
wastage.
For these reasons, we describe in this study a model
built to evaluate the cost-effectiveness of the easypod
auto-injector versus conventional devices for r-hGH treat-
ment in children with GHD in Italy.
A cost-consequence analysis is a variant of a cost-
effectiveness analysis that presents health-related out-
comes alongside costs and subsequently their relative
value between alternatives. A patient-level simulation,
decision-analytical model was developed to estimate the
cost-consequence of r-hGH treatment with the combina-
tion of somatropin (Saizen®, Merck) administered via
easypod, compared with other treatments for a hypotheti-
cal cohort of children with idiopathic growth hormone
deficiency (IGHD) in Italy. The model structure captures
the advantages of easypod over conventional devices in




This cost-consequence model consists of a decision tree
(Figure 1) and a Markov model (Figure 2). The decision
tree models how patients are evaluated in order to identify
poor adherence or poor response to r-hGH. The Markov
model represents the different levels of r-hGH use during
the course of treatment. Average cumulative drug costs
and height gained (in cm) per treatment arm were com-
puted. The model was developed in Microsoft Excel using
Visual Basic for Applications (VBA).
The analysis was performed on a cohort of 10,000
patients. The model followed the pre-defined number of
patients through the Markov model states, from the treat-
ment start age up to the full bone maturation age and
recorded the final height and drug costs for each patient.
The average height gained (in cm) at full bone maturation
age, total drug costs, drug wastage costs as well as costs
per cm gained for each treatment were estimated.
Baseline patient characteristics
In this model, 10,000 hypothetical patient profiles were
generated by sampling values of certain patient character-
istics: gender, age and height. The percentage of boys, the
upper and lower starting age of treatment as well as the
upper and lower HtSDS at the beginning of GH treatment
were defined for the cohort (Table 1). Age and height
samples were generated from uniform distributions:
Uniform (lowest age, highest age), Uniform (lowest
HtSDS, highest HtSDS). Using Italian reference heights
per age and gender,7 (Supplementary materials, Table S1)
the initial height of the patient was calculated as:
height ¼ mean heightð Þ þ HtSDS x
ðheight standard deviationÞ
In addition, the full bone maturation age (BA) was defined
for boys and girls as the age when adult height is reached,
and was considered as the end of treatment for each
individual in the cohort (18 years for girls and 19 years
for boys).8 It was assumed that there are no further height
gains after this age and the model calculations were
stopped.
Poor responders and poorly adherent
patients
During the treatment period, two reasons for growth failure
were considered in the model: (a) poor adherence and (b)
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poor response to r-hGH (resistance). It is assumed that part
of the cohort had lower r-hGH sensitivity and required a
higher GH dose to achieve clinical benefits (poor respon-
ders) while another part of the population was poorly
adherent and would not achieve the maximum clinical
benefits, as these children missed injections of GH com-
pared to the prescribed schedule of 6–7 injections per week.
Easypod can help physicians identify earlier and more
accurately the cause of growth failure. Using easypod
adherence recording files, the physician can detect these
patients earlier and adapt the GH dose for poor responders
if applicable or manage/motivate patients and caregivers to
improve adherence in the case of poor adherence to GH
treatment. Without a device being able to accurately record
adherence, a percentage of the poorly adherent patients are
falsely identified as poor responders (and could be subse-
quently overdosed, increasing costs and potential safety
risks). On the other hand, a percentage of the poor respon-
ders are likely to be not definitively confirmed, with the
subsequent consequence of being possibly under-dosed,
not achieving maximal growth response and eventually
decreasing the probability of adult height achievement.
The time until identification of the cause of growth failure
was included in the model. Time has an impact on the adult
height of low responding patients, as the model assumed that
their r-hGH dose was not adjusted until the evaluation date.
The link between adherence and years of therapy has been
shown to correlate negatively with years of therapy.9 For
patients using easypod, it was assumed that the evaluation of
response and adherence allows detection of poor responders
and poorly adherent patients after completion of the first 6
months (1 cycle). For patients using devices other than easy-
pod, it was assumed that identification of the cause of growth
failure did not occur until completion of 12 months of therapy
(2 cycles) as data on adherence are not available and growth
response is the main criteria used to define poor response and
subsequent action (Table 2).
When devices other than easypod (which do not
allow for adherence monitoring) were used for the
administration of the r-hGH, it was assumed that a
proportion of poorly adherent patients is diagnosed by
the physician as poor responders.10 To capture this part
of the treatment process, the proportion of poorly adher-



































Figure 1 Decision tree.
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poor responders (60%, assumption) were defined as
input parameters in the model (Table 2). Subsequently,
the percentage of patients who received an unnecessary
dose increase was calculated as the percentage of poorly
adherent patients multiplied by the percentage of those
falsely identified as poor responders (Table 2). This
subset of patients has an impact on the treatment costs,
as the improper dose increase is not considered to have
effects on patients’ adult height.
In case of poor adherence, the use of devices other than
easypod could also lead to a misdiagnosis of poor respon-
der incorrectly identified as poorly adherent patients. The
model used as inputs the percentage of poor responding
patients (resistance) and the percentage of patients that are
poor responders but not identified as such (Table 2).
Subsequently, the percentage of poor responding patients
Figure 2 Model states.
Table 1 Patient baseline characteristics
Gender21 Boys 66.0%
Girls 34.0%
Treatment start age (years)22 Lowest 2
Highest 12
Treatment start HtSDS22 Lowest −5.6
Highest −0.7
Age at full bone maturation (years)8 Boys 19
Girls 18
Abbreviation: HtSDS, height standard deviation score.
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that were identified as such was equal to the percentage of
poor responding patients (30%)10 minus the percentage of
patients that were poor responders not identified as such
(15%, assumption) (Table 2). For these patients, the model
assumes that r-hGH dose was increased thus increasing
costs and also adult height.
For poor responding patients not identified as such
(incorrectly diagnosed), the model assumes that r-hGH
dose was not adjusted, therefore without increasing drug
costs but also no benefit for adult height. These patients
remained indeed on the initial height percentile or main-
tained their HtSDS values until their bone maturation age,
even if they were adherent.
Model states
Each individual patient could transit in the model through
four states with a horizon equal to the treatment time (age
at full bone maturation minus the treatment start age). The
states were:
1. Continuous (continuously taking r-hGH)
2. Intermittent (missing a number of doses)
3. Discontinued (stopped taking r-hGH)
4. Achievement of bone age (skeletal maturity): model
termination.
During the first cycle, all patients entered in the 1) con-
tinuous state. The model structure and the possible transi-
tions are shown in Figure 2 alongside the transition
probabilities. Adherence data from Lass et al12 showing
that treatment adherence tended to be higher in children
treated with easypod than with another device for r-hGH
(easypod: 65% good, 35% medium/poor adherence; other
devices: 48% good, 52% medium/poor adherence) was
used to estimate the transition probabilities in the model.
Based on expert opinion, it was assumed that no patients
discontinued r-hGH treatment prior to their age of full
bone maturation.
Efficacy
The main parameter to measure the efficacy of r-hGH
treatment is height that represents the main goal of ther-
apy, ie, normalization of linear growth and achievement of
a “normal adult stature” with minimal risks and cost.13
HtSDS expresses height relative to standards for children of
the same age and sex, allowing comparisons that are indepen-
dent of age or gender. The normal population mean for height
corresponds to zero HtSDS and a normal HtSDS is included
between –2 and +2 standard deviations. Increase over time in
HtSDS (upward percentile crossing) implies catch-up growth
and a decrease implies growth failure. HtSDS was used to
define height gain in the first year of r-hGH treatment (Table
3). We used weighted averages from Ranke et al14 to calculate
the HtSDS gain for the first year (ages 2–12 years), with the
assumption that 40% of the population had severe GHD and
60% of the population had less severe GHD. We then extra-
polated the values for HtSDS gains from 13 to 19 years. After
the first year and during the treatment period, the HtSDS gains
Table 2 Parameters for low response and non-adherence identification
Source
Number of cycles until identification of cause of growth failure (without easypod) 2 Expert estimation
Poorly adherent patients (below 85% adherence) 24.4% Bagnasco et al 201711
Poorly adherent patients (falsely) identified as poor responders (without easypod) 60.0% Assumption
Patients receiving unnecessary dose increase (without easypod) 14.6% 24.4% x 60.0%
Poor responding patients 30.0% Bang et al 201210
Patients that are poor responders and not identified as such (without easypod) 15.0% Assumption




















Abbreviation: HtSDS, height standard deviation score.
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are determined by patient’s age, level of adherence, presence of
poor response (resistance) and total treatment time.
The relative reduction in HtSDS gains for each state is
defined in Table 4. In case of continuous treatment, it was
assumed that HtSDS gain declines by 25% compared to gain
obtained during the first year (assumption), while for intermit-
tent treatment (85.7% adherence),15 gain declines faster, ie, by
70% per year (assumption).
Resource use and costs
Details of drug usage, including r-hGH dose per kg (0.025 mg
per kg, based on the approved label),16 does increase in case of
poor responder identified patients (also based on the approved
label) and adherence in case of intermittent r-hGH use15 are
shown in Table 5.
Although it is not a direct input in the model, body mass
index (BMI) was used for the r-hGH dose calculations. For
each patient, the required r-hGH dose per age was calculated
using (sampled) height and BMI. Given that BMI of patients
with IGHD is similar to the healthy population (difference of
mean BMI SDS −0.1 up to −0.2),17 the Italian BMI tables
(Supplementary materials, Table S2) were used.7
Based on BMI and height, the daily dose was calcu-
lated using the following formula:
daily dose ¼ height2 x BMI x dose of r-hGH=kgð Þ
For the drug costs calculations, 30.25 days per month were
assumed. The dose per kg and the percent increase of the
dose have an impact on costs but not on adult patients’
height.
The prices of the products used in this analysis, their
cartridge size and the percentage of use in the Italian market
for each size are presented in Table 6. In the case-base
analysis, the listed drug prices were used from the Italian
official journal.18 A scenario analysis was also conducted
where the published tender prices were used (Table 7).19
Costs were discounted at a rate of 3% per year.20
Wastage
Easypod can be used in two ways: a) manual mode, enabling
the patient to self-administer partial doses when each cartridge
is nearly finished, thereby avoiding wastage of the remaining
contents or b) automatic mode avoiding two injections on the
days when a new cartridge is inserted in the device.21
Since the administration of partial doses in order to
finish each cartridge means that the patient has to undergo
two injections on the same day, in automatic mode the
daily dose is adjusted slightly (by +10% or +25% accord-
ing to the choice of the user or the health care profes-
sional), so that the entire contents of each cartridge can be
administered as complete doses. If the dose administered
has been adjusted to below the prescribed dose during the
use of a cartridge, when the next cartridge is inserted,
easypod will adjust the dose administered to exceed the
prescribed dose. In view of this compensation and the
magnitude of the dose adjustments, it may be concluded
that the patient will not be under- or over-treated. This
way, the contents of each cartridge are used optimally,
while avoiding the duplicate injections resulting from the
administration of partial doses when easypod is used in the
manual mode. In the model, we have assumed that the
automatic mode is enabled and the extent of adjustment is
10% (based on the most commonly used setting in Italy).
The calculation of wastage cost was implemented as part
of the model. During the treatment period, for each cycle, the
individually required r-hGH dose was calculated on patients’
actual height and BMI. For each product, given its cartridge
size, the wastage (mg/day) was calculated as follows:
Wastage per day ¼ ðremaining mg per cartridgeÞ 
ðnumber of daily doses per cartridgeÞ; where
Remaining mg per cartridge ¼ cartridge size 
ðnumber of daily doses per cartridgeÞ x ðdaily doseÞ
Number of daily doses per cartridge ¼ cartridge size 
daily dose
The cost of wastage was calculated as:
wastage cost ¼ wastage mg per dayð Þ x ðtreatment
time in daysÞ x ðdrug price per mgÞ
Table 4 Efficacy
Reduction in HtSDS gains per year for intermittent r-hGH
treatment
70%
Reduction in HtSDS gains per year for continuous r-hGH
treatment
25%
Abbreviation: HtSDS, height standard deviation score.
Table 5 Drug usage
Dose of r-hGH (mg) per kg 0.025
Dose increase if the patient is identified as a poor responder 40.0%
Adherence % for intermittent r-hGH treatment 85.7%
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Table 6 Drug costs – base case
Company Product cartridge size (mg) Price (euro) Cost
per mg
Use of product
Merck Serono Somatropin easypod 6 € 166.15 € 19.92 7%
Somatropin easypod 8 € 231.84 € 28.98 23%
Somatropin easypod 12 € 332.30 € 27.69 70%
Somatropin easypod 20 € 553.80 € 27.69 0%
Ipsen NutropinAq 10 € 208.59 € 20.86 100%
NutropinAq 10 € 0.00 € 0.00 0%
Lilly Humatrope 6 € 174.80 € 29.13 18%
Humatrope 12 € 250.20 € 20.85 56%
Humatrope 24 € 500.40 € 20.85 26%
Pfizer Genotropin 5 € 155.92 € 29.42 28%
Genotropin 12 € 317.71 € 26.48 72%
Sandoz Omnitrope 5 € 85.00 € 17.00 9%
Omnitrope 10 € 161.50 € 16.15 41%
Omnitrope 15 € 242.25 € 16.15 51%
Novo Nordisk Norditropin SimpleXx 5 € 129.46 € 25.89 20%
Norditropin SimpleXx 10 € 415.51 € 41.55 0%
Norditropin SimpleXx 15 € 388.38 € 25.89 80%
Ferring Zomacton 4 € 115.00 € 28.75 100%
Table 7 Drug costs – scenario analysis
Company Product Cartridge size (mg) Price (euro) Cost
per mg
Use of product
Merck Serono Somatropin easypod 6 € 100.86 € 17.30 7%
Somatropin easypod 8 € 138.40 € 17.30 23%
Somatropin easypod 12 € 207.60 € 17.30 70%
Somatropin easypod 20 € 346.00 € 17.30 0%
Ipsen NutropinAq 10 € 169.00 € 16.90 100%
NutropinAq 10 € 0.00 € 0.00 0%
Lilly Humatrope 6 € 106.14 € 17.69 18%
Humatrope 12 € 212.28 € 17.69 56%
Humatrope 24 € 424.56 € 17.69 26%
Pfizer Genotropin 5 € 94.34 € 17.80 28%
Genotropin 12 € 213.60 € 17.80 72%
Sandoz Omnitrope 5 € 69.25 € 13.85 9%
Omnitrope 10 € 138.50 € 13.85 41%
Omnitrope 15 € 207.75 € 13.85 51%
Novo Nordisk Norditropin SimpleXx 5 € 95.00 € 19.00 20%
Norditropin SimpleXx 10 € 190.00 € 19.00 0%
Norditropin SimpleXx 15 € 285.00 € 19.00 80%
Ferring Zomacton 4 € 103.80 € 25.95 100%
Dovepress Foo et al
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A threshold for the meaningful wastage (as a percentage of
the daily dose) was defined as 75%.16 This means that if
the remaining amount of drug, before a new cartridge was
inserted was lower than this threshold, then the remaining
was considered as wastage. In any other case, it was
assumed that the patient used the entire contents of the
cartridge.
Sensitivity analyses
In order to assess the impact of changes in key model
parameters on the model results, the following model
parameters were varied in one way sensitivity analyses;
discount rate (0%, 5%), percent of non-adherent patients
(falsely) identified as low responders (without easypod)
(±30%), percent of patients that are low responders and
not identified as such (without easypod) (±30%), transition
probabilities for somatropin with easypod, transition prob-
abilities for other r-hGH (±30%), per cent reduction in
HtSDS gains per year for intermittent r-hGH treatment
(±30%) and per cent reduction in HtSDS gains per year
for continuous r-hGH treatment (±30%). The model tested




In the base case analysis, patients using somatropin with
easypod achieved a height gain of 12.6 cm (estimated
adult height according to the model: 164.9 cm) whilst
patients receiving other r-hGH treatments achieved a
height gain of 9.4 cm (estimated adult height: 161.7 cm)
(Table 8). On average, patients receiving somatropin with
easypod gained 3.2 cm more than patients receiving other
r-hGH treatments (Table 8).
Table 9 presents detailed results of total costs, wastage
costs and cost per cm gained for each treatment. The
average total cost, including wastage, was calculated for
each drug. Somatropin with easypod was less expensive
than Zomacton and was more expensive than Nutropin,
Humatrope, Genotropin, Omnitrope and Norditropin
(Table 9). The cost of the wasted drug was lowest for
somatropin with easypod (€845), whilst for other r-hGH
treatments, it ranged from €1275 (Omnitrope) to €6102
(Zomacton) (Table 9).
While somatropin with Easypod had the second highest
total cost including wastage (€96,710), it had the second
lowest cost per cm gained (€7699/cm).
Scenario analyses
In the scenario analysis where published tender prices
were used,19 similar height gains were seen for both
arms as in the base case (Table 10). Total costs, including
wastage, were reduced substantially compared with the
total costs reported in the base case scenario (Table 11).
Somatropin with easypod showed the biggest reduction in
total costs (including wastage), with a reduction of
€37,495 (€59,215 vs €96,710) when compared with the
base case. The total costs (including wastage) for all other
comparators were also lower in the scenario analysis, with
reductions ranging from €8624 (Omnitrope) to €33,810
(Genotropin). As expected, the wastage costs also
decreased in line with the total costs.
Similar to the base case, somatropin with easypod had
the lowest wastage costs (€499) amongst all r-hGH
treatments.
Finally, this scenario analysis resulted in lower costs
per cm gained for all treatments, with somatropin with
easypod reporting the lowest cost per cm gained (€4708/
cm) amongst all treatments.
Sensitivity analyses
Five parameters impacted the overall conclusions of the
base case analysis and resulted in somatropin with easypod
having the third or fourth lowest cost per centimeter
gained; reducing the per cent of patients that are low
responders and not identified as such (without easypod)
by 30%, increasing the per cent reduction in HtSDS gains
per year for continuous r-hGH treatment by 30%, decreas-
ing the per cent reduction in HtSDS gains per year for
intermittent r-hGH treatment by 30%, decreasing the tran-
sition probability for the continuous state for Somatropin
with easypod by 30%, increasing the transition probability
for the continuous state for other r-hGH by 30%.
Discussion
This study is the first cost-consequence model to capture the
cost-effectiveness of somatropin with easypod relative to the
other licensed GH treatments in Italy. Many of the key model
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input data were derived from the literature and validated by a
local clinical expert. As much as possible, Italian data
sources were used (eg, for reference heights per age and
gender, BMI tables, drug costs) and this was particularly
important for scenario analysis where we used published
tender prices for GH to better reflect real-world costs.
The costs of competing r-hGH treatment options with
conventional devices without functions such as adherence
tracking and automatic dose adjustment play an important
factor in understanding the value of somatropin with easy-
pod. This value of easypod is driven by the functions
enabling physicians to earlier identify true poor responders
and manage adherence in real-time. This is further sup-
ported by improved adherence seen in clinical trials and
from real-world data.
The findings from the base case analysis using list
prices showed that the use of somatropin with easypod,
due to improved adherence and earlier identification of
poor responders, translated into an average incremental
height gain of 3.2 cm compared with other r-hGH treat-
ments. Whilst Somatropin with easypod had the second
highest total cost (€96,710), after Zomacton, it had the
second lowest cost per cm gained. In the scenario analysis
using tender prices, as to be expected, the incremental
height gains were comparable with the base case; however,
the findings for the total treatment costs, wastage costs and
subsequently the cost per cm gained were lower than in the
base case scenario.
The scenario analysis, which uses published tender
prices, better reflects the real-world costs of GH treat-
ments. The reductions in total costs (including wastage)
are driven solely by the lower prices achieved through the
regional tendering process in Italy. Somatropin with easy-
pod had the third lowest total drug cost (including
wastage) and the lowest cost per cm gained (€ 4708/cm)
in the scenario analysis using tender prices. It is important
to emphasize that in both the base case and scenario
analyses, wastage costs, as a percentage of the total drug
costs, were less than 1% for somatropin with easypod and
Table 9 Average costs – base case
Drug Total cost Wastage cost Cost per cm gained
Difference
Somatropin € 96,709.78 € 845.02 € 7699.33 N/a
Nutropin € 73,304.29 € 1626.94 € 7787.36 –€ 88.03
Humatrope € 78,097.87 € 1413.34 € 8296.59 –€ 597.27
Genotropin € 96,187.60 € 2412.98 € 10,218.33 –€ 2519.00
Omnitrope € 57,024.38 € 1274.64 € 6057.89 € 1641.44
Norditropin € 90,689.20 € 1620.20 € 9634.21 –€ 1934.89
Zomacton € 104,894.95 € 6101.92 € 11,143.34 –€ 3444.01











Table 11 Average costs – scenario analysis
Drug Total cost Wastage cost Cost per cm gained
Difference
Somatropin € 59,215.09 € 499.36 € 4708.08 N/a
Nutropin € 59,041.09 € 1311.27 € 6179.17 –€ 1471.09
Humatrope € 61,548.94 € 1120.51 € 6441.64 –€ 1733.56
Genotropin € 62,378.03 € 1573.84 € 6528.41 –€ 1820.33
Omnitrope € 48,400.02 € 1088.90 € 5065.49 –€ 357.41
Norditropin € 66,094.39 € 1191.05 € 6917.36 –€ 2209.28
Zomacton € 94,127.02 € 5482.71 € 9851.22 –€ 5143.15
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ranged from 1.8% to 6.2% with other hGH treatments.
Apart from changes to the drug costs (scenario analysis),
the five model parameters with the biggest impact on the
base case results were the percent of patients that are low
responders and not identified as such (without easypod),
percent reduction in HtSDS gains per year for continuous
r-hGH treatment, percent reduction in HtSDS gains per
year for intermittent r-hGH treatment, the transition prob-
ability for the continuous state for Somatropin with easy-
pod and the transition probability for the continuous state
for other r-hGH.
Two prior cost-effectiveness analyses have been pub-
lished exploring the impact of easypod in patients
with GHD.
Elashmawy et al 18 used a model very similar to ours
with inputs adapted for Egyptian children born with GHD.
They demonstrated that somatotropin delivered by easy-
pod was cost-saving compared with somatropin delivered
via prefilled syringe and cost-effective compared with
somatropin delivered via regular subcutaneous syringe.
Whilst the results of this study are generally in line with
our results, the focus of Elashmawy et al was on the
comparison of easypod with either prefilled syringes or
regular subcutaneous syringe (irrespective of the brand of
growth hormone).
Vitova et al19 performed a cost-utility analysis to compare
somatotropin delivered via easypod to standard non-moni-
tored somatotropin delivery. Interim results from the
Easypod Connect Observational Study were used to populate
a deterministic cohort model. Due to increased adherence of
monitored patients, the authors reported a cost-effective
incremental cost-effectiveness ratio (ICER) of 157,000
Czech Koruna. Whilst the type of cost-effectiveness analysis
(cost-consequence vs cost-utility) differed from our analysis,
their model also demonstrated improvements in efficacy of
GH treatment as a result of increased adherence through the
use of easypod to monitor treatment.
A limitation of our study is that there is a lack of
comparative studies for the alternative r-hGH options and
devices. The results of our analysis highlight the potential
height gains and cost savings that can be achieved through
the use of somatropin with electronic health solutions such
as easypod.
Conclusion
Treatment with somatropin with easypod results in
improved height gains compared with other r-hGH treat-
ments through better adherence and earlier identification
of poor responders. The easypod device also facilitates
cost savings in terms of reduced wastage. Somatropin
with easypod can be cost-saving versus all other r-hGH
treatments except Omnitrope when listed drug prices are
considered and can be cost-saving versus all other r-hGH
treatments when tender drug prices are considered.
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Supplementary materials
Table S1 Height
Age Age Boys Girls
Mean SD Mean SD
(years) (months) (cm) (cm) (cm) (cm)
2.0 24 88.8 4.4 87.2 3.7
2.5 30 93.1 4.5 91.4 3.9
3.0 36 97.0 4.6 95.4 4.1
3.5 42 100.7 4.7 99.2 4.3
4.0 48 104.1 4.8 102.8 4.4
4.5 54 107.4 5.0 106.4 4.6
5.0 60 110.7 5.0 109.7 4.8
5.5 66 113.8 5.1 113.0 4.9
6.0 72 116.8 5.2 116.1 5.0
6.5 78 119.8 5.4 119.2 5.3
7.0 84 122.8 5.5 122.0 5.4
7.5 90 125.6 5.6 124.8 5.5
8.0 96 128.4 5.7 127.6 5.6
8.5 102 131.1 5.8 130.3 5.8
9.0 108 133.8 5.9 133.1 5.9
9.5 114 136.4 6.0 135.9 6.0
10.0 120 139.0 6.0 139.0 6.2
10.5 126 141.6 6.1 142.2 6.5
11.0 132 144.3 6.2 145.5 6.7
11.5 138 147.1 6.4 148.8 6.9
12.0 144 150.2 6.5 151.9 7.1
12.5 150 153.5 6.8 154.6 7.1
13.0 156 157.2 7.4 156.8 7.0
13.5 162 161.0 7.8 158.4 6.9
14.0 168 164.6 8.4 159.7 6.6
14.5 174 167.8 8.6 160.6 6.4
15.0 180 170.4 8.6 161.2 6.3
15.5 186 172.3 8.4 161.7 6.2
16.0 192 173.7 7.9 162.0 6.1
16.5 198 174.7 7.5 162.2 6.0
17.0 204 175.3 7.1 162.3 6.0
Note: Data from Cacciari et al.1
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Table S2 BM
Age (years) Age (months) Boys (mean) Girls (mean)
2.0 24 16.5 16.1
2.5 30 16.1 15.8
3.0 36 15.9 15.7
3.5 42 15.8 15.6
4.0 48 15.8 15.6
4.5 54 15.8 15.7
5.0 60 15.8 15.8
5.5 66 15.9 15.9
6.0 72 16.0 16.1
6.5 78 16.2 16.2
7.0 84 16.3 16.4
7.5 90 16.5 16.6
8.0 96 16.8 16.9
8.5 102 17.0 17.1
9.0 108 17.3 17.4
9.5 114 17.6 17.7
10.0 120 18.0 18.1
10.5 126 18.3 18.5
11.0 132 18.7 18.9
11.5 138 19.1 19.4
12.0 144 19.5 19.8
12.5 150 19.9 20.1
13.0 156 20.2 20.4
13.5 162 20.6 20.6
14.0 168 20.9 20.8
14.5 174 21.1 20.9
15.0 180 21.3 21.0
15.5 186 21.5 21.0
16.0 192 21.7 21.0
16.5 198 21.8 21.1
17.0 204 21.9 21.1
Note: Data from Cacciari et al.1
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